While expectation might have been for more than 41% growth in Q1, AxoGen spent the first part of the quarter adding new sales management, new specialists, and generally investing in sales across the board, Jefferies analyst Raj Denhoy tells investors in a post-earnings research note. Despite the "noise," the company still posted 41% overall growth and guidance remains for a least 40% growth this year, with the emphasis on "at least," the analyst adds. He believes AxoGen remains a "best in medtech story" and keeps a Buy rating on the shares with a $45 price target.